Panacea Biotec Limited (NSE:PANACEABIO)

Panacea Biotec Statistics

Total Valuation

Panacea Biotec has a market cap or net worth of INR 26.37 billion. The enterprise value is 25.81 billion.

Market Cap	26.37B
Enterprise Value	25.81B

Important Dates

The last earnings date was Saturday, May 30, 2026.

Earnings Date	May 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Panacea Biotec has 61.25 million shares outstanding. The number of shares has decreased by -0.37% in one year.

Current Share Class	61.25M
Shares Outstanding	61.25M
Shares Change (YoY)	-0.37%
Shares Change (QoQ)	+6.16%
Owned by Insiders (%)	68.70%
Owned by Institutions (%)	0.15%
Float	15.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.02
PB Ratio	3.18
P/TBV Ratio	3.36
P/FCF Ratio	n/a
P/OCF Ratio	158.12
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 210.85, with an EV/FCF ratio of -68.99.

EV / Earnings	-480.59
EV / Sales	3.93
EV / EBITDA	210.85
EV / EBIT	n/a
EV / FCF	-68.99

Financial Position

The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.03.

Current Ratio	1.47
Quick Ratio	0.42
Debt / Equity	0.03
Debt / EBITDA	1.93
Debt / FCF	-0.63
Interest Coverage	-3.44

Financial Efficiency

Return on equity (ROE) is -0.86% and return on invested capital (ROIC) is -2.71%.

Return on Equity (ROE)	-0.86%
Return on Assets (ROA)	-1.02%
Return on Invested Capital (ROIC)	-2.71%
Return on Capital Employed (ROCE)	-2.28%
Weighted Average Cost of Capital (WACC)	5.93%
Revenue Per Employee	3.06M
Profits Per Employee	-24,988
Employee Count	2,149
Asset Turnover	0.51
Inventory Turnover	1.38

Taxes

Income Tax	-2.10M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.53% in the last 52 weeks. The beta is 0.28, so Panacea Biotec's price volatility has been lower than the market average.

Beta (5Y)	0.28
52-Week Price Change	-14.53%
50-Day Moving Average	367.14
200-Day Moving Average	382.05
Relative Strength Index (RSI)	63.17
Average Volume (20 Days)	210,167

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Panacea Biotec had revenue of INR 6.57 billion and -53.70 million in losses. Loss per share was -0.88.

Revenue	6.57B
Gross Profit	3.76B
Operating Income	-208.20M
Pretax Income	-73.70M
Net Income	-53.70M
EBITDA	122.40M
EBIT	-208.20M
Loss Per Share	-0.88

Balance Sheet

The company has 744.00 million in cash and 236.60 million in debt, with a net cash position of 507.40 million or 8.28 per share.

Cash & Cash Equivalents	744.00M
Total Debt	236.60M
Net Cash	507.40M
Net Cash Per Share	8.28
Equity (Book Value)	8.29B
Book Value Per Share	128.44
Working Capital	1.64B

Cash Flow

In the last 12 months, operating cash flow was 166.80 million and capital expenditures -540.90 million, giving a free cash flow of -374.10 million.

Operating Cash Flow	166.80M
Capital Expenditures	-540.90M
Depreciation & Amortization	330.60M
Net Borrowing	n/a
Free Cash Flow	-374.10M
FCF Per Share	-6.11

Margins

Gross margin is 57.29%, with operating and profit margins of -3.17% and -0.82%.

Gross Margin	57.29%
Operating Margin	-3.17%
Pretax Margin	-1.12%
Profit Margin	-0.82%
EBITDA Margin	1.86%
EBIT Margin	-3.17%
FCF Margin	n/a

Dividends & Yields

Panacea Biotec does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.37%
Shareholder Yield	0.37%
Earnings Yield	-0.20%
FCF Yield	-1.42%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3